Jaguar Health, Inc. - Common Stock, par value $0.0001 per share (JAGX)
CUSIP: 47010C888
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 6,991,905
- Total 13F shares
- 64,813
- Share change
- -29,973
- Total reported value
- $60,351
- Price per share
- $0.93
- Number of holders
- 10
- Value change
- -$27,924
- Number of buys
- 6
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 47010C888?
CUSIP 47010C888 identifies JAGX - Jaguar Health, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 47010C888:
Top shareholders of JAGX - Jaguar Health, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Lisa A. Conte |
3/4/5
|
Chief Exec. Officer & President, Director |
—
mixed-class rows
|
76,312
mixed-class rows
|
$473,128,965 | — | 11 Dec 2025 | |
| Jonathan B. Siegel |
3/4/5
|
Director |
—
mixed-class rows
|
33,262
mixed-class rows
|
$473,112,619 | — | 11 Dec 2025 | |
| Jonathan S. Wolin |
3/4/5
|
Chief of Staff, Chief Compliance Officer & General Counsel |
—
mixed-class rows
|
42,140
mixed-class rows
|
$473,111,818 | — | 11 Dec 2025 | |
| John Micek |
3/4/5
|
Director |
—
mixed-class rows
|
33,269
mixed-class rows
|
$473,104,383 | — | 11 Dec 2025 | |
| Pravin R. Chaturvedi |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
31,063
mixed-class rows
|
$75,720,294 | — | 11 Dec 2025 | |
| Lincoln Alternative Strategies LLC |
3/4/5
|
10%+ Owner |
8.6%
|
600,000
|
$1,284,000 | — | 28 Aug 2025 | |
| Joshua Mailman |
13D/G
|
— |
8.4%
|
587,320
|
$845,741 | $0 | 17 Dec 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
65,002
|
$779,374 | $0 | 20 May 2025 | |
| Iliad Research & Trading, L.P. |
13D/G
|
— |
9.8%
|
440,000
|
$748,000 | $0 | 11 Dec 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
4.6%
|
164,204
|
$346,470 | +$36,300 | 30 Sep 2025 | |
| Uptown Capital, LLC |
13D/G
|
John Fife and Fredrick Waid |
9.9%
|
1,290,000
|
$322,500 | $0 | 29 Jan 2025 | |
| DRW Securities, LLC |
13F
|
Company |
1.3%
|
90,968
|
$211,955 | — | 30 Sep 2025 | |
| Steven R. King |
3/4/5
|
Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary |
—
mixed-class rows
|
31,010
mixed-class rows
|
$87,466 | — | 11 Dec 2025 | |
| Carol R. Lizak |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
34,451
mixed-class rows
|
$20,248 | — | 11 Dec 2025 | |
| James J. Bochnowski |
3/4/5
|
Director |
—
mixed-class rows
|
68,168
mixed-class rows
|
$10,905 | — | 11 Dec 2025 | |
| Anula Jayasuriya |
3/4/5
|
Director |
—
mixed-class rows
|
11,786
mixed-class rows
|
$10,057 | — | 11 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.05%
|
3,381
|
$7,878 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
702
|
$2,000 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
220
|
$513 | — | 30 Sep 2025 | |
| Leonteq Securities AG |
13F
|
Company |
0%
|
188
|
$438 | — | 30 Sep 2025 | |
| Gregory J. Divis |
3/4/5
|
Director |
—
class O/S missing
|
12,133
|
$364 | — | 18 May 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
14
|
$33 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
10
|
$23 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
4
|
$9 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Sep 2025 |
Institutional Holders of Jaguar Health, Inc. - Common Stock, par value $0.0001 per share (JAGX) as of Q4 2025
As of 31 Dec 2025,
Jaguar Health, Inc. - Common Stock, par value $0.0001 per share (JAGX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,813 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, DRW Securities, LLC, XTX Topco Ltd, UBS Group AG, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Leonteq Securities AG, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, and BlackRock, Inc..
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
9
Q4 2025 holders
10
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.